MORE PATIENTS HAVE STARTED VUMERITY
THAN ANY OTHER BRANDED ORAL THERAPY FOR RMS IN THE US SINCE DECEMBER 20202,a
aBased on the cumulative number of new MS prescriptions for the months December 2020 through February 2023 per IQVIA NPA New to Brand, Patient Insights® monthly NBRx.
Efficacy and safety outcomes
from switch patients
Well-established, real-world safety
refill adherence data
Consistent support for